Cytokinetics, Incorporated – NASDAQ:CYTK
Cytokinetics, Incorporated stock price today
$38.69
-8.67
-18.31%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Cytokinetics, Incorporated stock price monthly change
-15.40%
month
Cytokinetics, Incorporated stock price quarterly change
-15.40%
quarter
Cytokinetics, Incorporated stock price yearly change
-43.24%
year
Cytokinetics, Incorporated key metrics
Market Cap | 5.72B |
Enterprise value | 3.96B |
P/E | -8.1 |
EV/Sales | 42.77 |
EV/EBITDA | -18.64 |
Price/Sales | 36.08 |
Price/Book | -30.97 |
PEG ratio | 0.14 |
EPS | -5.4 |
Revenue | 3.75M |
EBITDA | -475.68M |
Income | -530.59M |
Revenue Q/Q | -81.89% |
Revenue Y/Y | -96.17% |
Profit margin | -271.59% |
Oper. margin | -212.86% |
Gross margin | -78.98% |
EBIT margin | -212.86% |
EBITDA margin | -12678.12% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCytokinetics, Incorporated stock price history
Cytokinetics, Incorporated stock forecast
Cytokinetics, Incorporated financial statements
Average Price Target
$90
Potential upside: 132.61%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 867K | -128.63M | -14837.02% |
|---|---|---|---|
| Sep 2023 | 378K | -129.42M | -34238.62% |
| Dec 2023 | 1.67M | -136.89M | -8187.56% |
| Mar 2024 | 835K | -135.64M | -16244.67% |
| Jun 2023 | 779899000 | 1.11B | 142.71% |
|---|---|---|---|
| Sep 2023 | 740614000 | 1.17B | 159.25% |
| Dec 2023 | 824316000 | 1.21B | 146.87% |
| Mar 2024 | 808082000 | 1.20B | 149.02% |
| Jun 2023 | -121.80M | 82.12M | 5.47M |
|---|---|---|---|
| Sep 2023 | -96.20M | 73.03M | 54.21M |
| Dec 2023 | -74.03M | -81.41M | 168.8M |
| Mar 2024 | -129.50M | 32.64M | 103.79M |
Cytokinetics, Incorporated alternative data
| Aug 2023 | 409 |
|---|---|
| Sep 2023 | 409 |
| Oct 2023 | 409 |
| Nov 2023 | 409 |
| Dec 2023 | 409 |
| Jan 2024 | 409 |
| Feb 2024 | 409 |
| Mar 2024 | 423 |
| Apr 2024 | 423 |
| May 2024 | 423 |
| Jun 2024 | 423 |
| Jul 2024 | 423 |
Cytokinetics, Incorporated other data
100.00%
0.00%
of CYTK is owned by hedge funds
248
-7
97.26M
-7.92M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 58178 |
| Feb 2024 | 0 | 50105 |
| Mar 2024 | 0 | 32604 |
| Apr 2024 | 0 | 43167 |
| May 2024 | 0 | 15547 |
| Jun 2024 | 0 | 51879 |
| Aug 2024 | 0 | 36100 |
| Sep 2024 | 0 | 34684 |
| Oct 2024 | 0 | 31352 |
| Nov 2024 | 0 | 24384 |
| Dec 2024 | 0 | 14080 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | HENDERSON JOHN T director | Common Stock | 10,092 | $7.37 | $74,378 | ||
Option | HENDERSON JOHN T director | Common Stock | 1,780 | $7.37 | $13,119 | ||
Sale | HENDERSON JOHN T director | Common Stock | 1,780 | $50.42 | $89,748 | ||
Option | HENDERSON JOHN T director | Non-Qualified Stock Option (Right to Buy) | 1,780 | $7.37 | $13,119 | ||
Option | HENDERSON JOHN T director | Non-Qualified Stock Option (Right to Buy) | 10,092 | $7.37 | $74,378 | ||
Option | MALIK FADY IBRAHAM officer: EVP Rese.. | Common Stock | 5,300 | $7.96 | $42,188 | ||
Sale | MALIK FADY IBRAHAM officer: EVP Rese.. | Common Stock | 5,300 | $50.63 | $268,339 | ||
Sale | MALIK FADY IBRAHAM officer: EVP Rese.. | Common Stock | 2,000 | $50.65 | $101,300 | ||
Option | MALIK FADY IBRAHAM officer: EVP Rese.. | Non-Qualified Stock Option (Right to Buy) | 5,300 | $7.96 | $42,188 | ||
Option | BLUM ROBERT I director, officer.. | Common Stock | 5,000 | $6.67 | $33,350 |
| Patent |
|---|
Application Filling date: 11 May 2020 Issue date: 27 Aug 2020 |
Grant Utility: Tetrahydroisoquinoline derivatives Filling date: 4 Mar 2019 Issue date: 23 Jun 2020 |
Grant Utility: Compounds, compositions and methods Filling date: 28 Jun 2018 Issue date: 20 Aug 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 3 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering
Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook
Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
Cytokinetics, Incorporated: Buyout Speculation Persists
Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)
Aficamten Sets Cytokinetics Apart In Cardiomyopathy
Best Macro Pairs Trade Of 2023: Short ARKK And Long Healthcare
-
What's the price of Cytokinetics, Incorporated stock today?
One share of Cytokinetics, Incorporated stock can currently be purchased for approximately $38.69.
-
When is Cytokinetics, Incorporated's next earnings date?
Unfortunately, Cytokinetics, Incorporated's (CYTK) next earnings date is currently unknown.
-
Does Cytokinetics, Incorporated pay dividends?
No, Cytokinetics, Incorporated does not pay dividends.
-
How much money does Cytokinetics, Incorporated make?
Cytokinetics, Incorporated has a market capitalization of 5.72B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 92.04% to 7.53M US dollars.
-
What is Cytokinetics, Incorporated's stock symbol?
Cytokinetics, Incorporated is traded on the NASDAQ under the ticker symbol "CYTK".
-
What is Cytokinetics, Incorporated's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cytokinetics, Incorporated?
Shares of Cytokinetics, Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cytokinetics, Incorporated's key executives?
Cytokinetics, Incorporated's management team includes the following people:
- Mr. Robert I. Blum Chief Executive Officer, Pres & Director(age: 61, pay: $1,020,000)
- Dr. Fady Ibraham Malik Executive Vice President of R&D(age: 61, pay: $691,060)
- Mr. Mark A. Schlossberg Senior Vice President of Legal, Gen. Counsel & Sec.(age: 64, pay: $625,060)
- Mr. Ching W. Jaw Senior Vice President & Chief Financial Officer(age: 62, pay: $605,850)
- Mr. David W. Cragg Chief HR & Admin. Officer(age: 69, pay: $541,120)
-
How many employees does Cytokinetics, Incorporated have?
As Jul 2024, Cytokinetics, Incorporated employs 423 workers.
-
When Cytokinetics, Incorporated went public?
Cytokinetics, Incorporated is publicly traded company for more then 21 years since IPO on 30 Apr 2004.
-
What is Cytokinetics, Incorporated's official website?
The official website for Cytokinetics, Incorporated is cytokinetics.com.
-
Where are Cytokinetics, Incorporated's headquarters?
Cytokinetics, Incorporated is headquartered at 350 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact Cytokinetics, Incorporated?
Cytokinetics, Incorporated's mailing address is 350 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 06243000.
-
What is Cytokinetics, Incorporated stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Cytokinetics, Incorporated in the last 12 months, the avarage price target is $90. The average price target represents a 132.61% change from the last price of $38.69.
Cytokinetics, Incorporated company profile:
Cytokinetics, Incorporated
cytokinetics.comExchange:
NASDAQ
Full time employees:
423
Industry:
Biotechnology
Sector:
Healthcare
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
350 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001061983
ISIN: US23282W6057
CUSIP: 23282W605
